IMMUNITYBIO, INC. Construction Payable, Current
IMMUNITYBIO, INC. (IBRX) had Construction Payable, Current of $628.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Notes › Payables and Accruals › Accounts Payable and Accrued Liabilities, Current
us-gaap:ConstructionPayableCurrent · last filed 2025-03-03
- 2024-12-31: Construction Payable, Current $628.00K.
- 2023-12-31: Construction Payable, Current $1.18M.
- 2022-12-31: Construction Payable, Current $7.07M.
- 2021-06-30: Construction Payable, Current $2.89M.
| Period end | Construction Payable, Current |
|---|---|
| 2024-12-31 | $628.00K 10-K · filed 2025-03-03 |
| 2023-12-31 | $1.18M 10-K · filed 2025-03-03 |
| 2022-12-31 | $7.07M 10-K · filed 2024-03-19 |
| 2021-06-30 | $2.89M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $1.93M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $0.00 10-Q · filed 2021-08-12 |
| 2020-09-30 | $164.00K 10-Q · filed 2020-11-09 |
| 2019-12-31 | $0.00 10-Q · filed 2020-11-09 |
| 2019-09-30 | $0.00 10-Q · filed 2019-11-05 |
| 2019-06-30 | $949.00K 10-Q · filed 2019-08-06 |
| 2019-03-31 | $1.38M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $3.34M 10-K · filed 2020-03-25 |
| 2018-09-30 | $3.34M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $5.21M 10-Q · filed 2018-08-06 |
| 2018-03-31 | $5.02M 10-Q · filed 2018-05-07 |
| 2017-12-31 | $6.21M 10-K · filed 2019-03-13 |
| 2017-09-30 | $11.07M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $10.20M 10-Q · filed 2017-08-07 |
| 2017-03-31 | $1.26M 10-Q · filed 2017-05-08 |
| 2016-12-31 | $1.24M 10-K · filed 2018-03-12 |
| 2016-09-30 | $990.00K 10-Q · filed 2016-11-10 |
| 2016-06-30 | $610.00K 10-Q · filed 2016-08-15 |
| 2016-03-31 | $992.00K 10-Q · filed 2016-05-16 |
| 2015-12-31 | $132.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |